Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials Individual patient data of neoadjuvant RCTs ...

This research was funded by Eisai GmbH, Germany. Eisai GmbH was informed throughout the process of data collection and analyses, and contributed to the research through critical review of results ...

Broschüren - allgemeine Informationen zu den Herausgebern Broschüren Übergreifende Krebs-Themen Broschüren Brustkrebs Broschüren Gastrointestinale Tumoren Broschüren Urologische Tumoren Broschüren ...

Bei Erkrankungen mit niedrigem Risiko ist dies offenbar mit anderen Therapieansätzen möglich.

Die japanische Pharmafirma Eisai Co., Ltd. verzeichnet Anfang Februar 2025 eine stabile Kursentwicklung. Der aktuelle Aktienkurs beträgt 28,97 EUR und zeigt sich damit unverändert zum Vortag.

Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

(RTTNews) - Biogen Inc. (BIIB), a biotechnology company and Eisai Co., Ltd. On Friday provided an update on the regulatory review of lecanemab as a treatment for early Alzheimer's disease or AD in ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

BRÜSSEL (dpa-AFX) - Alzheimer-Patienten in der EU müssen weiter auf eine Zulassung einer ersten Therapie warten. Wie die ...

TOKYO -- Japanese drugmaker Eisai will make its Alzheimer's disease treatment Leqembi available for at-home administration by fiscal 2025 in the U.S., where thousands of patients are waiting to ...